Gan & Lee Pharmaceuticals Hits Day High with 4.84% Surge

Gan & Lee Pharmaceuticals Co., Ltd. has experienced a notable increase of 4.84% on June 18, 2026, reaching an intraday high of CNY 57.78. This performance stands in contrast to the China Shanghai Composite, which declined by 0.43% on the same day. Over the past week, Gan & Lee has shown a modest gain of 1.59%, while its monthly performance reflects a 3.81% increase, again outperforming the broader market. Despite a year-to-date decline of 16.7%, the company has demonstrated resilience with a significant annual return of 37.52%, surpassing the market's 20.71% return over the same period. Financial metrics indicate a robust growth trajectory, with net sales increasing by 23% in the latest half-year results. The company has also reported positive results for the last eight consecutive quarters, showcasing a return on capital employed (ROCE) of 8.23%. Gan & Lee's market capitalization stands at CNY 29,735 million, and it maintains a competitive dividend yield of 1.8%. The stock's performance metrics highlight its position within the pharmaceuticals and biotechnology sector, reflecting a complex landscape of growth and valuation.